

# Randomised trial of surgical resection with or without pre-operative chemotherapy in patients with operable non-small cell lung cancer (NSCLC) of any stage

<b>Submission date</b> 06/04/2000	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 06/04/2000	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 22/10/2018	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Prof Ian Smith

### Contact details

Department of Oncology  
Royal Marsden Hospital  
Downs Road  
Sutton  
United Kingdom  
SM2 5PT  
+44 (0)20 8642 6011  
abc@123.com

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

NCT00003159

## **Secondary identifying numbers**

LU22

# **Study information**

## **Scientific Title**

Randomised trial of surgical resection with or without pre-operative chemotherapy in patients with operable non-small cell lung cancer (NSCLC) of any stage

## **Study objectives**

To compare survival following surgical resection with or without pre-operative chemotherapy.

Secondary aims are to compare:

1. QL throughout the survival period; all items on the SF-36 questionnaire will be used to assess physical, emotional and functional health status, with particular emphasis on items that reflect the impact of symptoms on activities
2. Pre-randomisation clinical and post-surgery pathological staging
3. Resectability rates
4. Extent of surgery
5. Time to and site of relapse

And chemotherapy group, to document response evaluated according to the subjective investigators opinion following the WHO (1979) criteria, and clinician's assessment of the adverse effects of chemotherapy.

## **Ethics approval required**

Old ethics approval format

## **Ethics approval(s)**

Not provided at time of registration

## **Study design**

Randomised controlled trial

## **Primary study design**

Interventional

## **Secondary study design**

Randomised controlled trial

## **Study setting(s)**

Hospital

## **Study type(s)**

Treatment

## **Participant information sheet**

**Health condition(s) or problem(s) studied**

Non-small cell lung cancer (NSCLC)

**Interventions**

1. One group receives surgical resection with pre-operative chemotherapy.
2. The other group receives surgical resection alone.

**Intervention Type**

Other

**Phase**

Not Specified

**Primary outcome measure**

Survival, quality of life, pre-randomisation clinical and post-surgery pathological staging, resectability rates, extent of surgery, time to and site of relapse

**Secondary outcome measures**

1. QL assessed before randomisation at 6 and 12 months from randomisation, and then annually, using the SF-36 questionnaire. All items and subscales will be examined according to the SF-36 manual. Analysis will be based on comparisons between regimens at the designated time points and on change from baseline for each regimen
2. Pre-randomisation clinical and post-surgery pathological staging
3. Resectability rates
4. Extent of surgery
5. Time to and site of relapse

**Overall study start date**

01/07/1997

**Completion date**

29/07/2004

**Eligibility****Key inclusion criteria**

1. Previously untreated non small cell lung cancer
2. Tumour considered resectable
3. Either sex, any age
4. No evidence of distant metastases
5. Considered fit for chemotherapy and proposed surgical resection
6. WHO performance status 0, 1 or 2
7. No contraindication to chemotherapy or surgery
8. No other disease or previous malignancy likely to interfere with the protocol treatments
9. Patient willing and able to complete SF-36 questionnaires

**Participant type(s)**

Patient

**Age group**

Not Specified

**Sex**

Both

**Target number of participants**

600

**Key exclusion criteria**

Not provided at time of registration.

**Date of first enrolment**

01/07/1997

**Date of final enrolment**

29/07/2004

## **Locations**

**Countries of recruitment**

England

United Kingdom

**Study participating centre**

**Department of Oncology**

Sutton

United Kingdom

SM2 5PT

## **Sponsor information**

**Organisation**

Medical Research Council (MRC) (UK)

**Sponsor details**

20 Park Crescent

London

United Kingdom

W1B 1AL

+44 (0)20 7636 5422

clinical.trial@headoffice.mrc.ac.uk

**Sponsor type**

Research council

**Website**

<http://www.mrc.ac.uk>

## Funder(s)

**Funder type**

Research council

**Funder Name**

Medical Research Council (MRC) (UK)

**Alternative Name(s)**

Medical Research Council (United Kingdom), UK Medical Research Council, MRC

**Funding Body Type**

Government organisation

**Funding Body Subtype**

National government

**Location**

United Kingdom

## Results and Publications

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Plain English results</a>				No	Yes
<a href="#">Results article</a>	results	09/06/2007		Yes	No